Nektar Therapeutics (NKTR) stock is lower by -23.82% over the last 12 months, and the average rating from Wall Street analysts is a Buy. InvestorsObserver’s proprietary ranking system, gives NKTR stock a score of 29 out of a possible 100.
That rank is chiefly influenced by a short-term technical score of 14. NKTR’s rank also includes a fundamental score of 31. In addition to the average rating from Wall Street analysts, NKTR stock has a mean target price of 28.272. This means analysts expect the stock to rise 14.23% over the next 12 months. The long-term technical score for NKTR is 43.
What’s Happening with NKTR Stock Today
Nektar Therapeutics (NKTR) stock is up 4.92% while the S&P 500 is higher by 0.84% as of 3:08 PM on Wednesday, Jul 15. NKTR is higher by $1.16 from the previous closing price of $23.59 on volume of 601,104 shares. Over the past year the S&P 500 has risen 7.34% while NKTR is lower by -23.82%. NKTR lost -$2.62 per share in the over the last 12 months.